Abstract 803P
Background
Japanese Gynecologic Oncology Group (JGOG) 2043 was a trial to assess the efficacy of three different chemotherapeutic regimens as adjuvant therapy in endometrial cancer (EC) patients with post-operative recurrent risk. Inflammation predisposes patients to tumorigenesis by damaging DNA, stimulating angiogenesis, and potentiating pro-proliferative and anti-apoptotic processes. This study investigated whether pre-treatment systemic inflammatory markers (PTSIMs) are associated with survival outcomes in EC.
Methods
Women with EC were recruited to the JGOG 2043 study, excluding patients who did not receive chemotherapy and those lost to follow-up. PTSIMs, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and hemoglobin, albumin, lymphocyte, and platelet (HALP) score were analysed in terms of clinicopathological factors, progression-free survival (PFS), and overall survival (OS). Optimal cut-off values for NLR, PLR, and HALP score were determined using the web application Cutoff Finder for PFS and OS. Survival estimates were calculated using the Kaplan–Meier method. Differences in survival between groups were assessed using a log-rank test.
Results
In total, 712 patients were enrolled in the JGOG 2043 study, with a median age of 59 years (interquartile range (IQR), 52–64) and body mass index (BMI) of 22.4 kg/m2 (IQR 19–25). The optimal cut-off values for PFS were 1.478 for NLR, 0.01695 for PLR, and 35.52 for HALP score. Similarly, the optimal cut-off values for OS were 1.88 for NLR, 0.02623 for PLR, and 19.87 for HALP score. Regarding the optimal cut-off values for PFS, NLR was associated with BMI; PLR with age, BMI, and surgical stage; and HALP score with BMI, surgical stage, and lymph node metastasis. For the optimal cut-offs for OS, NLR was associated with BMI, PLR, and BMI; and HALP score was associated with age and BMI. In PFS, HALP score was the prognostic factor (NLR: p=0.068; PLR: p=0.086; HALP score: p=0.025). In OS, PLR and HALP score were prognostic factors (NLR: p=0.1; PLR: p=0.028; HALP score: p=0.028).
Conclusions
PTSIMs are associated with survival outcomes in EC. In particular, HALP score was a prognostic factor for both PFS and OS.
Clinical trial identification
UMIN000036755.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11